Patient-Derived Models

Explore the utility of patient-derived models, including organoids, patient-derived xenografts (PDX), and patient-derived tumor organoids (PDTO), for studying cancer stem cell biology and drug screening. This track highlights the advantages and limitations of different patient-derived model systems, offering insights into their relevance for understanding tumor heterogeneity, drug response, and therapeutic resistance. Discover how patient-derived models are shaping preclinical drug development and personalized medicine approaches in oncology, offering new opportunities for translational research and therapeutic innovation.

    Related Conference of Patient-Derived Models

    March 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    London, UK
    March 24-25, 2025

    10th World Conference on Breast and Cervical Cancer

    Paris, France
    April 28-29, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    May 26-27, 2025

    15th World Congress on Breast Cancer

    Rome, Italy
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    October 13-14, 2025

    8th International Conference on Anti-Cancer Drugs & Therapies

    Aix-en-Provence, France
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain

    Patient-Derived Models Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in